Virbac is a French publicly listed animal health company generating approximately $1.4 billion in 2024 revenue, ranking among the global top eight by revenue. Portfolio spans companion animals, livestock, and aquaculture, with specialty positions in dental care, dermatology, parasiticides, and reproduction. Operations cover 100+ countries with significant production capacity in France, the U.S., Australia, and India.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.

Strategic priorities include accelerating the companion animal franchise through specialty therapeutics, growing the U.S. business that doubled following the 2015 Sentinel acquisition, and Asia-Pacific aquaculture expansion. R&D investment runs at approximately 9% of revenue. Strengths include balanced portfolio across companion and production animals, family-controlled stable governance with public-market discipline, and strong R&D intensity. Risks include FX volatility, parasiticide brand competition, and modest scale relative to global leaders.

Topics Covered
• Corporate Overview and History
• Strategic Directions and 2026-2030 Priorities
• Financial Performance and Segment Breakdown
• SWOT Analysis
• Business Segment Analysis
• Technology and Innovation Pipeline
• M&A, Partnerships and Licensing Activity
• Competitive Positioning Against Top 10 Peers
• Strategic Conclusions and Outlook